How to Help Your Patients Find Elahere in Stock: A Provider's Guide

For gynecologic oncologists and medical oncologists treating platinum-resistant ovarian cancer, Elahere (mirvetuximab soravtansine-gynx) is a paradigm-shifting option — the first FRα-directed antibody-drug conjugate to demonstrate an overall survival benefit in PROC. But as many practices know, translating FDA approval into timely patient access involves navigating multiple steps. This guide outlines a practical approach for helping your patients get Elahere as quickly as possible.

Step 1: Order FRα Testing Early — Don't Wait for a Third-Line Decision

The biggest access delay for Elahere is often the FRα testing timeline. The companion diagnostic — the VENTANA FOLR1 (FOLR-2.1) RxDx Assay — must be completed before treatment can begin, and results from reference labs may take 1-2 weeks.

Best practice: Order FRα testing at the time you determine a patient has platinum-resistant disease — before you need a third-line therapy decision. This way, you have results in hand when the decision point arrives, avoiding an unnecessary delay to treatment.

Submit archival FFPE tissue to a reference lab running the VENTANA FOLR1 assay — a new biopsy is not always needed.

Confirm the lab has sufficient tissue. If not, arrange for rebiopsy promptly.

About 35% of patients with high-grade serous ovarian cancer will have high FRα expression qualifying for Elahere.

Step 2: Enroll Patients in ELAHERE Support Services Before the PA Is Filed

AbbVie's ELAHERE Support Services (ESS) program offers dedicated Case Managers who handle insurance prior authorization, financial assistance, and specialty pharmacy coordination. Having them involved from the start reduces delays.

Submit the ESS enrollment form as soon as you've decided to prescribe Elahere — ideally before the PA is submitted.

ESS Case Managers can often identify whether your patient's specific plan has a history of covering Elahere and can prepare a stronger PA submission accordingly.

ESS phone: 1-833-ELAHERE (1-833-352-4373)

Step 3: Build a Strong Prior Authorization Package

A comprehensive PA package dramatically improves approval rates and speed. Include:

FRα-positive VENTANA FOLR1 assay results (lab report)

Documentation of platinum-resistant disease (progression within 6 months of last platinum dose)

Summary of prior treatment lines (1-3) with agents and dates

Reference to FDA full approval (March 22, 2024) and NCCN Category 1 designation in ovarian cancer guidelines

Letter of medical necessity citing MIRASOL efficacy data: OS HR 0.67, p=0.0046; ORR 42.3% vs 15.9%; this is the first therapy to show an OS benefit in PROC

Step 4: Confirm Infusion Center Capability and Eye Care Access

Elahere requires IV administration (6 mg/kg AIBW every 3 weeks) at a qualified oncology infusion center. Before scheduling the patient's first infusion, confirm:

The infusion center's pharmacy can order and prepare Elahere from a specialty pharmacy supplier.

An ophthalmologist or optometrist can see the patient before the first dose and on the required schedule thereafter (every other cycle for first 8 cycles). Ideally within the same health system.

Prescribe prophylactic lubricating eye drops and ophthalmic topical steroids before the first infusion — the label requires this, and proactive prescribing reduces ocular toxicity severity.

Step 5: Manage Access Gaps — What to Do While Waiting for Approval

The PA process averages 2-4 weeks. If a patient is symptomatic or has rapidly progressing disease, consider a bridging chemotherapy regimen (e.g., weekly paclitaxel or PLD) while awaiting authorization. Document this clinical urgency in the PA itself and request an expedited review.

Step 6: Use medfinder for Patients Who Need Help Finding a Facility

For patients in underserved areas or those who live far from major cancer centers, medfinder for providers can help identify infusion facilities within a reasonable distance that are equipped to administer Elahere. This is particularly useful when referring a patient to a different practice or when your own facility does not administer Elahere.

Premedication Protocol Reminder

Per the prescribing information, all patients must receive premedication approximately 30 minutes before each Elahere infusion:

Antihistamine (e.g., diphenhydramine 25-50 mg PO/IV)

Corticosteroid (e.g., dexamethasone 8 mg PO/IV)

Acetaminophen 650 mg PO

For more clinical context on supply and availability, see: Elahere Shortage: What Providers and Prescribers Need to Know in 2026.